serum insulin-like growth factor-1 and nitric oxide levels in parkinsons disease血清胰岛素样生长因子- 1在帕金森病和一氧化氮水平.pdf

Hindawi Publishing Corporation Mediators of Inflammation Volume 2009, Article ID 132464, 4 pages doi:10.1155/2009/132464 Clinical Study Serum Insulin-Like Growth Factor-1 and Nitric Oxide Levels in Parkinson’s Disease Deniz Tuncel,1 Fatma Inanc Tolun,2 and Ismail Toru2 1 Department of Neurology, Faculty of Medicine, Kahramanmaras Sutcu Imam University, 46050 Kahramanmaras, Turkey 2 Department of Biochemistry, Faculty of Medicine, Kahramanmaras Sutcu Imam University, 46050 Kahramanmaras, Turkey Correspondence should be addressed to Deniz Tuncel, tuncedeniz@ Received 12 May 2008; Revised 19 October 2008; Accepted 5 January 2009 Recommended by Jan van Amsterdam The aim of this study was to investigate the role of circulating growth hormone (GH), insulin growth factor-1 (IGF-1), IGF binding protein-3 (IGFBP-3), and nitric oxide (NO) concentrations in the patients suffering from Parkinson’s disease (PD). The study groups were consisted of 25 patients with PD and 25 matched healthy subjects as a control. The NO level of patients in PD group (2.3 ± 0.4 µmol/L) was significantly lower than that in the control group (2.8 ± 0.6 µmol/L) (P:.011). Although there were no statistically significant differences in the GH, IGF-1, and IGF BP-3 levels among the two groups, in this preliminary study, we found low NO and mildly elevated IGF-1 levels in the patients with PD. The results may be associated with adaptation or protective mechanisms in the neurodegenerative disease processes such as seen in the PD. Further studies should be carried out to confirm our results. Copyright © 2009 Deniz Tuncel et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original wo